Expert Interview
Discussing the recent data from Takeda's phase 2b trial of TAK-861 as a treatment for patients with narcolepsy.
Ticker(s): TAK, JAZZInstitution: Stanford
- Clinical Associate Professor, Neurology & Neurological Sciences & Clinical Associate Professor, Psychiatry and Behavioral Sciences - Sleep Medicine at Stanford.
- Manages 40 patients with narcolepsy and has prescribed SUNOSI.
- Research interests involve biomarkers of disease progression in REM sleep behavior disorder, and mechanisms and treatment of Postural Tachycardia Syndrome and Post-Acute COVID Syndrome; special interest in Autonomic Disorders, Sleep Disorders, and the interaction between these conditions.
Roughly how many patients do you currently manage with narcolepsy?
Added By: ben_adminDescribe your practice setting and background
Added By: ben_adminWhat are your high level thoughts on the potential of TAK-861?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
